Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Neurocrine Biosciences posts strong Q2 revenue growth and raises 2026 sales guidance.
NBIX
$166.95
-$18.55 -10.00%

Neurocrine Biosciences posts strong Q2 revenue growth and raises 2026 sales guidance.

Company Fundamentals
31 Jul 2026
Alex Lavoie
View Source
Bullish
pluang ai news

Neurocrine Biosciences reported a 39% increase in Q2 2026 revenues to $959 million and non-GAAP earnings of $2.85 per share, beating estimates. Sales of its key drug INGREZZA rose 15% year-over-year, prompting the company to raise its 2026 sales forecast to $2.825-$2.875 billion. The company is also growing through the acquisition of Soleno Therapeutics and expects important Phase III clinical trial results in 2027, supporting a positive outlook from analysts like Citigroup.

More News (NBIX)

Neurocrine Biosciences Q2 revenue rises 39%, boosts 2026 sales forecast after Soleno acquisition

Neurocrine Biosciences Q2 revenue rises 39%, boosts 2026 sales forecast after Soleno acquisition

Neurocrine Biosciences reported a 39% year-over-year revenue increase to $959 million in Q2 2026, driven by strong sales of INGREZZA, CRENESSITY, and new product VYKAT XR following its acquisition of Soleno Therapeutics. The company raised its full-y...

Company Fundamentals
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App